H. E. Logue, M.D.

100 Century Park South - Suite 206

Birmingham, AL  35226

Phone:  (205)978-7800

Fax: (205)978-7802

E-Mail:  heloguemd@amhsinc.net

Web Site: www.heloguemd.com

CURRENT POSITIONS:

            Psychiatrist – Private practice Birmingham, July 1972 – present

Medical Director, Geriatric Behavioral Medicine, Baptist Medical Center, June 2006 – present

Founder, Chief Medical Officer and Chairman of the Board,

American Behavioral Benefits Managers, a Mental Health managed benefits and EAP company, October 1989 – present

Medical Director/Founder

Birmingham Psychiatry Pharmaceutical Studies, Inc., November 1992 – present

President/founder Venture Mental Health Management, a psychiatric consulting and services company 1987- present

Appointment to Impaired Physicians Assessment and Treatment Panel of Alabama, 1992 – present

DST Health Solutions, Inc. – National UM/QI Committee 2003 – 2010

President/founder November 1 2004 Affiliated Mental Health Services, Inc. – present

PREVIOUS POSITIONS AND EXPERIENCE

            Medical Director – Chief of Psychiatry Section UAB Medical West 2004 – April 2006

President (founder July 1972) of Birmingham Psychiatry, P.A. to 2004

Member of Psychiatric Steering Committee Brookwood Medical Center

For Mental Health 1973 – 2003

Medical Director, Adult Inpatient Services

            Brookwood Medical Center, September 1996 – July 2003

            Medical Director of Development Brookwood Center for Mental Health,

            October 1987 – July 2003

Member Brookwood Medical Center Psychiatry Quality Assurance/

Process Improvement Committee, 1986 – 2003

Medical Director, Birmingham Chapter, Manic Depressive-Depressive Organization of the National Organization 1993-2002

Medical Director, Partial Hospital Program,

Brookwood Medical Center, January 1992 – 2001

Medical Director for Cebert Pharmaceuticals, Inc, 1997-2000

Founding Board Member and Medical Director of PsychPartners, LLC,

A practice management company 1995 – July 1998

State Mental Health Director of Correctional System

November 1991 – October 1994

Public Relations Officer, Alabama Psychiatric Society,

A district branch of the American Psychiatric Association 1991-1992

President, Alabama Psychiatric Society (Now Alabama Psychiatric Physicians Association) 1990-1991

Founder of Department of Psychiatry, Brookwood Medical Center,

January 1974. Chairman of Department from 1974 – 1986 (Three four-year terms)

Medical Director, Brookwood Medical Center for Mental Health

September 1, 1985 – October 1, 1987

Member of Executive Committee, Brookwood Medical Center

January 1974 – December 1986, ex officio member 1986-1987

Member of Governing Board of Brookwood Medical Center

Ex officio 1986-1987

Chairman Steering Committee to develop Brookwood’s PPO-

Physician’s Preferred Provider Comprehensive Health Care Organization

1992-1995

Appointed as Assistant Professor of Psychiatry to UAB Medical Center 1980-1984

Member Divisional Medical Advisory Counsel and Regional Medical Advisory Counsel –

American Medical International representing Brookwood Medical Center 1983-1988

Member Brookwood Medical Center Long-Range Planning Committee 1983-1988

Vice-President Center for Mental Health Brookwood Hospital

October 1, 1986 – October 1, 1987

Medical Director, Atlantic Plasma Research Organization 1969-1971

HOSPITAL AFFILIATIONS

(1)               Brookwood Medical Center

(2)               Baptist Medical Center – Princeton

(3)               St. Vincent’s Hospital

EDUCATIONAL BACKGROUND

1969 – 1972  Psychiatric Residency at the Medical College of Georgia,

Augusta, Georgia

1963 – 1964 One year rotating internship University Hospital,

Augusta, Georgia

1963 Medical College of Georgia, August Georgia – M.D. Degree

Graduated Emory University, Atlanta, Georgia, 1958, BA Degree

Associate Degree, Emory at Oxford, Georgia, 1955

Graduated Tennille High School, Washington County, Georgia, 1953

BOARD STATUS AND CERTIFICATIONS

American Board of Psychiatry and Neurology – eligible (never sat for Board)

Diplomate of the American Board of Forensic Examiners #9898, 1996

Diplomate of the American Board of Forensic Medicine #9898, 1997

Diplomate and Senior Analyst of American Board of Disability Analysts #42909, 1997

PREPSYCHIATRIC MEDICAL EXPERIENCE

1964 – 1969 General and family practice North Augusta, South Carolina

Hospital Affiliations

(1)               University Hospital, Augusta, Georgia 1964-1969

(2)               St. Joseph Hospital, Augusta, Georgia 1964-1969

Chief of General Practice Section – 1967

HONORS

            Distinguished Life Fellow, American Psychiatric Association, January 1, 2012

Named to Best Doctors in America 2011-2014

2007 Named to America’s Top Psychiatrists listing by Consumers’ Research Council

1998 Annual National Exemplary Psychiatrist Award from National Alliance of the Mentally Ill

1996 Mental Health Professional of the Year Award by Birmingham Alliance for the Mentally Ill

U.S. Neuroscience Advisory Board – Eli Lilly & Co. 1996-1999

Astra-Zenica Regional Advisory Board

Elected member Who’s Who Worldwide 1994-1995 Edition,
Lifetime Member

National Registry of Who’s Who, 2001 Edition

President, Alabama Psychiatric Society

A district branch of the American Psychiatric Association 1990-1991

1989 – 1990 President-Elect Alabama Psychiatric Society

Governor’s appointment to Medical Advisory Board for Corrective Systems

In Alabama, January 1983-1985

Awarded Honorary Assistant Attorney General – Alabama awarded 1983

Elected Secretary of State Chapter Gamma Kappa Alumni Society of Theta Kappa Psi

Medical fraternity  1963-1974

1955 awarded scholastic scholarship to attend Emory University for the following year

March 1955 inducted in Phi Delta Omega Science honor fraternity for premedical and

predental students at Emory at Oxford

PROFESSIONAL ORGANIZATIONS AND MEMBERSHIPS

(1)               American Psychiatric Association

(2)               American Medical Association (terminated membership 2010)

(3)               American College of Physician Executives

(4)               Alabama Psychiatric Physicians Association (A District Branch of American Psychiatric Association)

(5)               Jefferson County Medical Society

(6)               Medical Association of State of Alabama

(7)               Central Alabama Psychiatric Society

(8)               The American College of  Forensic Medicine (inactive)

(9)               The American College of Forensic Examiners (inactive)

(10)           The American College of Physician Executives

(11)           The American Board of Disability Analysts

MILITARY SERVICE

            Enlisted in Army National Guard, 1955, Private E-1,

Transferred to Army Reserves, 1957

Honorable Discharge, 1974, Captain (eligible for Major)

CIVIC AND SECULAR ORGANIZATIONS        

Managing Partner, Birmingham Professional Associates I & II

Associates owned POB: 1984-1999 when property was sold.

Served as Coordinator for United Way for psychiatrists of Jefferson County 1987

Member of Board of Advisors for State organization of

Mental Health Technicians 1976

National Alliance for the Mentally Ill, Birmingham, Alabama

Member of Board of Birmingham Crisis Center 1976-1980 (+/-)

Served as Executive Committee member 1979-1980

President, Taino Gardens Condominiums Homeowner’s Association

Freeport, Grand Bahama Island, Bahamas 1984 – Present

Board member, Edgewater Condominium Association – Destin, Florida 2001-Present

PUBLICATIONS

Published Books:

Author, Addiction: Yours, Mine, and Ours, published 2010 (category: applied psychology)

Author, Fly Me to the Moon: Bipolar Journey through Mania and Depression, published 2006, winner of EVVY Merit Award (category: fiction) from the Colorado Independent Publishers Association; also published in Iran. This is the only fiction novel awarded CME credit status.

Professional consultant to Uncle Arthur’s Storytime Children’s True Adventures,

Published 1989

Published Articles:

Consultant for article, “Kicking the Smoking Habit” published by Foundation for a

Healthy Life, Volume 6, No. 2

Served as consultant for article on “Depression” for Health Sense, 1982

Served as consultant for article on “Senility” for publication in the

Birmingham Business Journal, 1985

Author of article, “Anxiety in the Work Place” for publication in the

Birmingham Business Journal, 1985

Author of article to Southeast Health Plan newsletter, “Dealing with Holiday

Depression”, 1987

Consultant to Vim and Vigor magazine for article on “Depression”, 1996;

OCD in Summer of 1997 and Schizophrenia in Fall of 1997

PAPERS AND TALKS (Scientific and Community Education)

Ethics Meets Thanatos – Presented to Fourteenth Invitational Scientific Symposium

Of the Medical Association of the State of Alabama.  January 24, 1998

Atypical Antipsychotics (What Is Here and What Is Coming) – Presented to Fourteenth Invitational Scientific Symposium of the Medical Association of the State of Alabama,

January 24, 1998

Stress history and dealing with it, Alabama Pulmonary Association, 1987

Talk to Jaycettes, 1966-Women’s Relative Position in Society, a historical perspective

Authored Monograph on Psychiatry and the Law, presented as a 3 hour lecture at Tuskegee Institute, 1982

Numerous talks at various hospitals and county medical societies on depression and anxiety.

Talks to department of medicine at Brookwood Medical Center on several occasions on topics of anxiety, depression, the seductive patient, etc.

Educational Outreach Program.  For several years, I presented talks to county medical societies as an educational outreach program of Brookwood Medical Center, giving approximately two lectures per year on mental health topics.  I am currently doing the same thing for Baptist Medical Center Princeton. 

Presented grand rounds at Brookwood Medical Center Department of Psychiatry several times, topics including depression, anxiety, the seductive patient, stress, milieu therapy and others

Talk to South Alabama  Psychiatric Society 1991; “50 Years Changes/Progress in Medicine”

Talk to Department of Psychiatry, Ochsner Clinic, New Orleans, Louisiana 1993,

Living with Managed Care

National Speaking Circuit regarding New Horizons in Treatment of Schizophrenia

1996 – 1999, by Pragmaton, a CME organization

Numerous talks to various civic groups including Rotary clubs, churches, Kiwanas, radio programs and TV appearances (1964 – present) covering the following topics:

            Psychiatry

            Religion

            Dreams

            Depression

            Anxiety

            Suicide in youth and prevention

            Drug abuse and prevention

            Commitment

            Success vs. Failure

            Hypnosis

            Holiday depression

            Bipolar Disorder

            Schizophrenia

            New psychiatric medicines for depression and schizophrenia

            New antipsychotic medications; present at several southern cities

            Numerous talks to psychiatric communities through the South on the

                        new atypical antipsychotics

            Weight control

            Addiction

RESEARCH EXPERIENCE

1. Principal Investigator

“Insomnia treatment study”

The Upjohn Company 1992

2. Principal Investigator

“Fluvoxamine vs. Placebo in the treatment

of Panic Disorder”

Enrolled:  20 patients (6 months) 1992-1993

3. Principal Investigator

“Fluvoxamine vs. Placebo in the treatment of

Panic Disorder: A long-term maintenance,

Double Blind study company efficacy and safety”

Enrolled: 20 patients (6 months)

The Upjohn Company/Pharmaco 1993-1994

4. Principal Investigator

“A Randomized, comparative open-labeled study

of Paroxetine in the Treatment of Depression as

used in a Clinical Practice Setting”

Smith-Kline Beecham/Clin-Trials

Enrolled: 20 patients (3  months) 1993-1994

5. Principal Investigator

“Olanzapine vs. Haloperidol in the Treatment of

Schizophrenia and Other Psychotic Disorders (HGAJ)

Enrolled: 44 patients (12 months)

Eli Lilly/Pharmaco 1994-1995

6. Principal Investigator

“Imitrex Injections in the Treatment of Migraine Headaches”

Enrolled:  40 patients (2 months) 1994

7. Principal Investigator

“Epidemiologic Survey of Prostep”

Enrolled:  20 patients 1993-1994

8. Principal Investigator

“A Double-Blind Placebo-controlled, dose response

comparison of the safety and efficacy of three doses

of Sertindole and three doses of Haldol in Schizophrenic

Patients” (M930113) Abbott Laboratories – Inpatient Study

Enrolled:  34 patients (6 months) 1994-1995

9. Principal Investigator

“An Open-label Assessment of the long-term safety

of Sertindole in the treatment of Schizophrenic patients”

(M92-795)

Enrolled: 17 patients (Continuous Study from M93-113)

Abbott Laboratories  1995

10. Principal Investigator

“An Open-label Assessment of the Safety of Sertindole” (M94-222)

Enrolled:  15 patients (Continuation Study from M93-ll3)

Abbott Laboratories  1995

11. Principal Investigator

“A Phase II comparative study using a single dose of

Acetaminophen, Acetaminophen/Cyproheptadine, Cyproheptadine

Alone and Placebo in the Treatment of Migraine Headache”

McNeil Laboratories  1994-1995

12. Principal Investigator

“A prospective, Multi-center, Open-label study of Serzone

(nefazodone) in the Management of Patients with Symptoms

of Depression in General Psychiatric Practices”

(CN 104-127)

Enrolled:  14 patients (3 months)

Bristol-Myers Squibb/ICRC  1995

13. Principal Investigator

“Olanzapine vs. Risperidone in the Treatment of Schizophrenia

and other Psychotic Disorders” (FID-MC-HGBG)

Enrolled: 49 patients (4 months)

Eli Lilly  1995

14. Sub Investigator

“A Multi Center, Placebo-Controlled Study of Relapse Prevention

By Long-Term Treatment with High or Low Doses of ORG-4428

In Outpatients with Recurrent Major Depressive Episode”

Enrolled:  35 patients

Organon/Pharmaco

15. Principal Investigator

“Open Label Experience with Olanzapine in Patients Who Have

Completed a Previous Olanzapine Clinical Trial” protocol,

(Compassionate Use Study) (HGDI)

Enrolled: 13 patients from previous Olanzapine Studies

Eli Lilly   February 1996

16. Sub Investigator

“A Randomized Double-Blind, Placebo-Controlled parallel group

multicenter, single dose range – finding study to assess the

efficacy and tolerability of VML 251 in the acute treatment of migraine”

Vanguard Medica Limited/Pharmaco

April 1996 to June 1996

17. Principal Investigator

“Mazapertine dose finding trial – comparing three fixed dosages

if Mazapertine to Risperidone and placebo: multicenter, double-blind

parallel group study”

Janssen Pharmaceutical Research Foundation

March  1996 to July 2, 1996

Inpatient Study  Phase II Clinical Trial

Screened: 23 patients   Randomized:   20 patients

18. Principal Investigator

“A Comparison of Risperidone and Haloperidol for Prevention

of Relapse in Subjects with Schizophrenia and Schizoaffective Disorders:

Enrolled:  24 patients

Janssen Pharmaceutical Research

Outpatient study

19. Sub Investigator

“An Open-Label, Multicenter Trial Evaluating the Safety

and Efficacy  of Donepezil Hydrochloride in Patients with

Alzheimer’s Disease”

Outpatient

Pfizer Pharmaceutical

20. Principal Investigator

“A Multi-Center, Double-Blind, Randomized Comparison of

Zolmitriptan and Sumatriptan in the Acute Treatment of

Multiple Migraine Headaches”

Outpatient

Zeneca Pharmaceutical

21. Principal Investigator

“A Multi-Center, Double-Blind, Randomized, Placebo Controlled,

Parallel Group Study of the Efficacy and Safety of Escalating

The Dose of Oral Eletriptan in Subjects with Acute Migraine”

Pfizer

22. Principal Investigator

“A 12 Month Study of VML251 In the Acute Treatment of Migraine”

Vanguard Medical Ltd.

Principal Investigator

“A Multi-Center, Randomized, Double-Blind, Placebo and Active

Controlled Study of MDL 100-907 in Schizophrenic and

Schizoaffective Patients”

Hoechst Marion Roussel, Inc.

23. Principal Investigator

“A Multi-Center, Open-Label, Long-Term follow-up, Safety

Study of MDL 100-907 in Schizophrenic and Schizoaffective

Patients Who Participated in Protocol  100907 PR0015

Hoeschst Marion Roussel, Inc.

24. Principal Investigator

“A Phase III, Randomized, Multi-Center, Open-Label study

Evaluating the Tolerance and Safety of 3 Days of Treatments

With Intramuscular Ziprasidone (20 to 80 mg. daily) or Haloperidol

(up to 40 mg. daily) followed by 4 days of Treatment with Oral Ziprasidone

(40 to 200 mg. daily) or Haloperidol in subjects with a Diagnosis of Psychotic Disorder”

Pfizer

25. Principal Investigator

“Risperidone vs Olanzapine in the Treatment of Schizophrenia

in Elderly Subjects”  RIS-INT-50

Outpatient Study

Janssen Research Foundation

26. Principal Investigator

“Risperidone vs Olanzapine in the Treatment of Schizophrenia”

RIS-USA-112

27. Principal Investigator

“Risperidone vs Olanzapine in the Treatment of Schizophrenia”

RIS-USA-113

28. Principal Investigator

“Fluvoxetine Augmentation in Schizophrenic or Schizoaffective

Patients with Depressive or Nonresponders to Olanzapine”

FID-MC-HGFT Outpatient study

Eli Lilly

29. Principal Investigator

“Strategies for switching from Conventional Antipsychotic Drugs

to Olanzapine”.

FID-MC-HGFW Outpatient study

Eli Lilly

30. Principal Investigator

“Olanzapine Added to Mood Stabilizers in the Treatment of

Bipolar Disorder”.

FID-MC-HGFU  Outpatient study

Eli Lilly

31. Sub-Investigator

“Metrifonate Investigational Nationwide Trial”

(M.I.N.T.) D97-019

Bayer Corporation

32. Principal Investigator

“The Safety and Efficacy of Risperdal (Risperidone) vs.

Placebo vs. Haloperidol as Add on Therapy to Mood Stabilizers

In the Treatment of the Manic Phase of Bipolar Disorder.

RIS-USA-102 Inpatient/Outpatient

Janssen Pharmaceutical Research Foundation

July 1998

33. Principal Investigator

“A Multicenter, Randomized, Double-Blind, parallel Group

Trial Comparing the Safety and Efficacy of Risperidone and

Olanzapine in the Treatment of Psychosis in Patients with

Schizophrenia and Schizoaffective Disorder (9 weeks).

RIS-USA-112 Outpatient Study

Janssen Pharmaceutical Research Foundation

November 1997-April 1998

34. Principal Investigator

“A Multicenter, Randomized, Double-Blind, Parallel Group

Trial Comparing the Safety and Efficacy of Risperidone and

Olanzapine in the Treatment of Psychosis in Patients with

Schizophrenia and Schizoaffective Disorder (44 weeks),

RIS-USA-113 Outpatient Study

Janssen Pharmaceutica Research Foundation December 1997

35. Principal Investigator

EMD 68 843

“A Double-Blind Randomized, Multicenter, Parallel Design Study to

Evaluation the Efficacy and Safety of Individual Maximum Tolerated

Doses of EMD 68 843 in Comparison with Placebo and Fluoxetine in

Outpatients with Major Depressive Disorder.

Merck KgaA

Outpatient Study  April 1998

36. Principal Investigator

Sanofi DFI 3077

“A Double-Blind, Placebo and Haloperidol Controlled Multicenter Study

Evaluating the Safety and Efficacy of SR 46349B, Protocol DFI 3024

Or SR 48692, Protocol DFI 3067 or SR 141716, Protocol DFI 3077 or SR 142801,

Protocol DFI 3138 in Schizophrenic Patients”. 

Sanofi Inpatient/Outpatient Study

September 1998

37. Principal Investigator

ABA 451

“A Prospective, Randomized, International, Parallel-Group

Comparison of Clozaril/Leponex vs. Zyprexa in the Reduction of

Suicidality in Patients with Schizophrenia or Schizoaffective Disorder

Who are at Risk for Suicide”.

Novartis Outpatient Study

May 1998

38. Principal Investigator

“Phase II, Six-Week, Double-Blind, Placebo and Olanzapine-Controlled

Study Evaluating the Safety and Efficacy of Oral CP-361, 428 in

Schizophrenia and Schizoaffective Disorder”

Schizophrenia Study

Pfizer 245-102 Inpatient study

Pfizer

39. Principal Investigator

“A Double-Blind, Randomized, Multicenter, Parallel Group Design Study

to Evaluate the efficacy of Two Dose Ranges of EMD 128 130 in

Comparison with Placebo and Haloperidol in the Treatment of Schizophrenia”

EMD 128-130-08

Schizophrenia study

Inpatient/Outpatient Study

Merck KgaA Pharmaceutical Co.

40. Principal Investigator

“A Prospective, Randomized, Double-Blind, Placebo and active-controlled,

multicenter study to evaluate the efficacy and safety of three fixed doses

of Iloperidone (4, 8 and 21 mg/d) given b.i.d. for 42 days to schizophrenic

patients with acute or subacute exacerbation, followed by a double-blind,

active-controlled, flexible-dose, long-term, 6-month phase with Iloperidone

(4, 8, 12 or 16 mg/d) given q.d.”

ILP 3000 schizophrenia

Inpatient and Outpatient Study

Novartis

41. Principal Investigator

“The Assessment of Nizatidine for the Prevention of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia

HGIJ Outpatient Study

Eli Lilly

42. Principal Investigator

Protocol:  F1D-MC-HGHL

“Olanzapine Versus Placebo in the Prevention of Relapse in

Bipolar Disorder”

HGIJ Outpatient Study

Eli Lilly

43. Principal Investigator

Protocol: F1D-MC-HGHL

“Oanzapine Versus Placebo in the Prevention of Relapse in

Bipolar Disorder”

HGHL Outpatient Study

Eli Lilly

44. Principal Investigator

“Prevalence of Hyperprolactemia in Schizophrenic Patients Treatees

with Antipsychotic Drugs”

Prolactin Study

HGHC Outpatient Study

Eli Lilly

45. Principal Investigator

“Allelic Variation in Schizophrenia”

HGGL Outpatient Study

Eli Lilly

46. Principal Investigator

Protocol: F1D-MC-HGHZ

“The Combination of Olanzapine and Fluoxetine in

Treatment Resistant Depression without Psychotic

Features”

HGHZ Outpatient Study

Eli Lilly

47. Principal Investigator

“Randomized, double-blind, placebo-controlled multicenter trial to

demonstrate the clinical efficacy and safety of two different doses of

Ginko biloba special extract Egb 761 in patients suffering from

Dementia of the Alzheimer’s Type according to DSM-IV and

NINCDS/ADRA criteria.”

Schwabe Protocol 523001-01-030

Alzheimer’s Study

Outpatient study

Schwabe

48. Principal Investigator

“A Double-Blind, Placebo-Controlled Dose-Finding Study Evaluating the

Safety and Efficacy of MKC-242 1.5, 6, and 24 mg/day (0.5, 2, and 8 mg. tid)

       the Treatment of Major Depressive Disorder.”

MKC/A01

Depression study

Outpatient study

Mitsubishi

49. Principal Investigator

“Safety and Efficacy of MKC-242 in the treatment of Major Depressive Disorder:

A 4 month double-blind extension to study MKC242-A01.”

MKC/A02

Depression study

Outpatient study

Mitsubishi

50. Principal Investigator

“Safety of open-label standard therapy in the treatment of Major Depressive

Disorder: A 1 month follow-up after termination of study MKC-242/A01.”

MKC/A03

Depression study

Outpatient study

Mitsubishi

51. Principal Investigator

“A Double-Blind, Placebo and Haloperidol-Controlled, Multicenter

Study Evaluating the Safety and Efficacy of SR141716 in Schizophrenic

Patients”

Sanofi 3077

Schizophrenia study

Inpatient study

52. Principal Investigator

Abbott M99-010

“Safety and Efficacy of Depakote as Combination Therapy in the Treatment

of Psychosis Associated with Schizophrenia.”

Inpatient study

Abbott Laboratories

Inpatient study

53. Principal Investigator

Protocol No. CN138-070 and CN138-010

“A Multicenter, Randomized, Double-Blind, Placebo Controlled Study

of Aripiprazole in the Maintenance Treatment of Patients with Bipolar

Disorder.”

Bristol-Myers Squibb Pharmaceutical Research Institute

Inpatient/Outpatient study

54. Principal Investigator

Protocol No. F1D-MC-HGIJ

“The Assessment of Nizatidine for the Prevention of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia.”

Outpatient study

Sponsor: Eli Lilly

55. Principal Investigator

Protocol No. F1J-MC-HMAT

“Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of

Major Depression.”

Sponsor: Eli Lilly

56. Principal Investigator

Protocol No. F1D-US-HGJB

“A Controlled Trial of Olanzapine Versus Quetiapine in the Treatment

of Schizophrenic and Schizoaffective Subjects with Prominent Negative

Symptoms.”

Outpatient study

Sponsor: Eli Lilly

57. Principal Investigator

Protocol No. F1J-MC-HMBH

“Duloxetine Once-Daily Dosing Versus Placebo in the Acute Treatment

of Major Depression.”

Outpatient study

Sponsor: Eli Lilly

58. Principal Investigator

Protocol No. TAK 637-00-302

“A Phase II Randomized, Multicenter, Placebo- and Active Controlled

Study of Oral TAK-637 in Subjects with Major Depressive Disorder.”

Outpatient Study

Sponsor: TAP Pharmaceutical Products, Inc.

59. Principal Investigator

Protocol No. FID-MC-HGGY

“Placebo – Controlled Olanzapine Monotherapy in the Treatment of

Bipolar I Depression”

Outpatient Study

Sponsor: Eli Lilly

60. Principal Investigator

Protocol No. F1D-MC-HGJN

“The Assessment of Amantadine for the Treatment of Olanzapine-

Associated Weight Gain in Patients with Schizophrenia, Schizophreniform,

Schizoaffective and Bipolar I Disorder.”

Outpatient Study

Sponsor: Eli Lilly

61. Principal Investigator

Protocol No. ILP 3005

“A randomized, double-blind, placebo- and risperidone controlled

multicenter study to evaluate the efficacy and safety of two nonoverlapping

dose ranges of iloperidone given b.i.d. for 42 days to Schizophrenic patients

followed by a long-term treatment phase with iloperidone given q.d.”

Inpatient and outpatient study

Sponsor: Novartis

62. Principal Investigator

Weight loss Study with carbohydrate restriction to 100 grams per day. 

63. Principal Investigator

“A Phase III, Randomized, Placebo-Controlled Study Evaluating the

Safety and Outcome of Treatment with Oral Ziprasidone in subjects

with Mania.”

128-601 Inpatient/Outpatient Study

Pfizer

64. Principal Investigator

“An Open Extension Study Evaluating For Safety and outcome of 40-160 mg.

daily of Ziprasidone in Previous Ziprasidone Clinical Trials.”

128-601 Inpatient/Outpatient Study

Pfizer

65. Principal Investigator

“A Double-Blind, Randomized, Multicenter, Parallel Design Study to

Evaluate the Efficacy and Safety of Individual Maximum Tolerated Doses

of EMD 68 843 in Comparison with Placebo and Fluoxetine in Outpatients

with Major Depressive Disorder.”

Merck EMD Outpatient Study

Merck KgaA

66. Principal Investigator

Protocol No. D105006

“A Double-Blind, Randomized, Fixed Dose, Placebo-Controlled, Parallel-Group

6-Week, Efficacy, Safety, and Tolerability Study of Two Dose Levels of

SM-13496 in Patients with Schizophrenia by DSM-IV Criteria Who Are

Experiencing an Acute Exacerbation of Symptoms.”

Sponsor: Sumitomo

Inpatient/Outpatient Study

67. Principal Investigator

Protocol No. 5077US/0043

“A Multicenter, Double-blind, Randomized Comparison of the Efficacy and Safety of

Quetiapine Fumarate (SEROQUEL) and Risperidone (RISPERDAL) in the Treatment of

Patients with Schizophrenia.”

Sponsor: AstraZeneca

Inpatient/Outpatient Study

68. Principal Investigator

B99.CT3.005.BUS P02

“A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Fixed-Dose

Study of the Efficacy, Safety, and Tolerability of 60 mg Buspirone

Hydrochloride Extended Release Compared to Placebo in Patients with

Generalized Anxiety Disorder”

Sponsor: Biovail

Outpatient Study

69. Principal Investigator

“An Open-Label Study of the Safety, and Tolerability, and Efficacy of Up to

90 mg Buspirone Hydrochloride Extended Release in Patients with Generalized

Anxiety Disorder.”

B99.CT#3.008.BUS P02

Sponsor: Biovail

Outpatient Study

70. Principal Investigator

Protocol #: Biovail B01.016.BUS P02

“A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-

Dose Study of the Efficacy, Safety, and Tolerability of 60 mg Buspirone

Hydrochloride Extended Release Compared to Placebo in Patients with

Generalized Anxiety Disorder Who Have Stable Disease Characteristics.”

Sponsor: Biovail

Outpatient Study

71. Principal Investigator

Protocol:

“An Acute and Continuation Phase Study of the Comparative Efficacy

of Venlafaxine ER (Effexor XR) and Fluoxetine (Prozac) in

Achieving and Sustaining Remission (Wellness) in Patients with

Recurrent Unipolar Major Depression; Followed by a Long-term

Randomized, Placebo-Controlled Maintenance Treatment Study in

Patients Treated Initially with Venlafaxine ER”

Sponsor: Wyeth-Ayerst Pharmaceuticals

Outpatient Study

72. Principal Investigator

Protocol:

“An International, Multicenter, Large Simple Trial (LST) To Compare

the Cardiovascular Safety of Ziprasidone and Olanzapine”

Sponsor: Pfizer, Inc.

Outpatient Study

73. Principal Investigator

Protocol: D1050049

“A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group

Study of the Efficacy and Safety of Three Dose Levels of SM-13496

Compared to Placebo and Haloperidol in Patients with Schizophrenia Who

Are Experiencing an Acute Exacerbation of Symptoms”

Sponsor: Sumitomo Pharmaceuticals America, Ltd.

Inpatient/Outpatient Study

74. Principal Investigator

Protocol: D1050174

“An Open-Label, Dose Blinded, Multicenter, 6 Month Study of Safety and

Tolerability of 3 Dose Levels of SM-13496 in Patients with Schizophrenia”

Sponsor: Sumitomo Pharmaceuticals America, Ltd.

Outpatient Study

75. Principal Investigator

Protocol:

“A Phase III, Randomised, Placebo-Controlled, Double-Dummy Study

Evaluating the Safety and Efficacy of Oral Ziprasidone vs. Haloperidol

And Placebo in In-Patients with an Acute Manic Episode”

Sponsor: Pfizer Inc.

Inpatient/Outpatient Study

76. Principal Investigator

Protocol:

“A Phase III, Three-Week, Multicenter, Randomized, Double-Blind,

Placebo-Controlled, Parallel-Group Safety and Efficacy Study of

Extended-Release Carbamazepine in the Treatment of Bipolar Disorder”

Sponsor: Shire Pharmaceutical Development Inc.

Inpatient/Outpatient Study

77. Principal Investigator

Protocol:

“A Pilot Study of the Effect of Hormone Replacement Therapy In

Recently Postmenopausal Women with Subjective Complaints”

Sponsor: Wyeth Pharmaceuticals Inc.

Outpatient Study

78. Principal Investigator

Protocol: 190-052

“Depression Response to Eszopiclone in Adults with Major Depressive

Disorder: A Randomized, Double-Blind, Placebo-Controlled, Parallel-

Group, 8-Week, Safety and Efficacy Study of Eszopiclone 3 mg

Compared to Placebo in Subjects with Insomnia Related to Major

Depressive Disorder”

Sponsor: Sepracor

Outpatient Study

79. Principal Investigator

Protocol: R209130-SCG-202

“A Randomized, Double-Blind, Placebo-Controlled, Dose-Response

Study of R209130 in Subjects with Schizophrenia Who Have

Predominantly Negative Symptoms”

Sponsor: Johnson & Johnson

Inpatient/Outpatient Study

80. Principal Investigator

Protocol: D1447C00135

“A Confirmatory Multicenter, Double-Blind, Randomized, Placebo-

Controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in

the Treatment of Patients with Bipolar Depression”

Sponsor: Astra-Zeneca

Outpatient Study

81. Principal Investigator

Protocol: D1447C00127

“A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III

Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral

Tablets 400 mg to 800 mg daily in divided doses) to Placebo When Used as

Adjunct to Mood Stabilizers (Lithium or Divalproex) in the

Maintenance Treatment of Bipolar Disorder in Adult Patients”

Sponsor: Astra-Zeneca

Outpatient Study

82. Principal Investigator

Protocol: D1444C00133

“A 6-week, Multicenter, Double-blind, Double-dummy, Randomized

Comparison of the Efficacy and Safety of Sustained-Release

Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the

Treatment of Acutely Ill Patients with Schizophrenia”

Sponsor: Astra-Zeneca

Outpatient Study

83. Principal Investigator

Protocol: R076477-SCH-304/704

“A Randomized, Double-Blind, Placebo- and Active-Controlled,

Parallel-Group, Dose-Response Study to Evaluate the Efficacy and

Safety of Two Fixed Dosages of Extended Release OROS

Paliperidone (6 and 12 mg/day) and Olanzapine (10 mg/day) with

Open-label Extension, in the Treatment of Subjects with

Schizophrenia”

Sponsor: Johnson & Johnson

Inpatient/Outpatient Study

84. Principal Investigator

Protocol: F1J-MC-HMDT

“Duloxetine Hydrochloride Once Daily Compared with Placebo

in the Treatment of Generalized Anxiety Disorder”

Sponsor: Eli Lilly

Outpatient Study

85. Principal Investigator

Protocol: A1281136

“A Six-Week, Randomized, Double-Blind, Multicenter, Fixed-

Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy

and Safety of Oral Ziprasidone in Outpatients with Bipolar I

Depression”

Sponsor: Pfizer Inc.

Outpatient Study

86. Principal Investigator

Protocol: R092670-PSY-3005; Phase 3

“A Randomized, Crossover Study to Evaluate the Overall Safety and

Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus

Muscle in Subjects with Schizophrenia”

Sponsor: Johnson & Johnson

Outpatient Study

87. Principal Investigator

Protocol: 190-902

“The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects with

Insomnia Related to Generalized Anxiety Disorder (GAD)”

Sponsor: Sepracor

Outpatient Study

88. Principal Investigator

Protocol: SGS518-CL03

“A double-blind, placebo-controlled, dose-ranging, parallel-group study in adults

with cognitive impairment associated with schizophrenia (CIAS)”

Sponsor: Saegis

Outpatient Study

89. Principal Investigator:

Protocol:  D1444KC0002

"A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-controlled and

Active-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate

Sustained-release (SEROQUEL) as Monotherapy in the Treatment of Patients with

Major Depressive Disorder (Diamond Study)”

Sponsor: AstraZeneca                        

Outpatient Study

90. Principal Investigator:

Protocol: D14448C0010

"A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Active-

Controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate

(SEROQUEL) Compared with Placebo in the Treatment of generalized Anxiety

Disorder" (Gold Study)

Sponsor: AstraZeneca                        

Outpatient Study

91. Principal Investigator

Protocol: A7501013

"A Multicenter, Double-Blind, Flexible-Dose, 6-Month Trial Comparing the Efficacy and

Safety of Asenapine with Olanzapine in Stable Subjects with Predominant, Persistent

 Negative Symptoms of Schizophrenia"

Sponsor: Pfizer/Organon

Outpatient Study

92. Principal Investigator

 Protocol: A7501014

 "A Multicenter, Double-Blind, Flexible-Dose, 6-Month Extension Trial Comparing Safety

and Efficacy and of Asenapine with Olanzapine in Subjects who Completed Protocol

 A750113"

      Sponsor: Pfizer/Organon

      Outpatient Study

93. Principal Investigator

            Protocol: A1281136

            "A Six-Week, Randomized, Double-Blind, Multicenter, Fiwd-Flexible Dose, Placebo-

            Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients

with Bipolar I Depression"

      Sponsor: Pfizer Inc.                           

      Outpatient Study

94. Principal Investigator

Protocol: 190-904

"A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects with

 Primary Chronic Insomnia"

      Sponsor: Sepracor                    

      Outpatient Study

95. Principal Investigator

Protocol: EFC5116

           "An eight week multicenter, double-blind, placebo- and escitalopram-controlled study

evaluating the efficacy and tolerability of two fixed doses of SSR149415 (250 mg bid

and 100 mg bid) in outpatients with major depressive disorder"

Sponsor: (Sanofi-Aventis)              

Outpatient Study

96. Principal Investigator

Protocol: DVS SR 3151A1-403

"A Multicenter, Randomized, 8-Week, Double-Blind, Placebo-Controlled Study

Followed by a 6-Month, Open-label Extension to Evaluate the Efficacy and Safety of

DVS SR in Peri- and Post-Menopausal Women with Major Depressive Disorder"

Sponsor: Wyeth                      

Outpatient Study

97. Principal Investigator

Protocol: S154.3.020

"A Multicenter, open-label, parallel-group, randomized, flexible dose study to evaluate

the safety and tolerability of switching from existing atypical antipsychotics to

            bifeprunox in subjects with schizophrenia or schizoaffective disorder”

Sponsor: Solvay

98. Principal Investigator

Protocol: D144CC00002

"A Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled, Phase

III Study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel) Sustained-

Release as Monotherapy in Adult patients”

Sponsor: AstraZeneca

99. Principal Investigator

Protocol:  LTE6673

"Efficacy and Safety of 2mg/day of Ml00907 on Sleep Maintenance Insomnia with a

sub-study of the effect of M100907 on stable Type II Diabetes Mellitus: a One Year,

multi-center, randomized, double-blind, placebo-controlled study"

Sponsor: Sanofi-Aventis

 100. Principal Investigator

Protocol: CAGO178A2302

Novartis Protocol Entitled: An 8-week, randomized, fixed-dosage, placebo-

controlled, parallel-group, multi-center study of the efficacy, safety and

tolerability of agomelatine 25 and 50 mg in the treatment of Major Depressive

Disorder (MDD)

 101. Principal Investigator

         Protocol: R092670-PSY-3006

         “A Randomized, Double-Blind, Parallel Group Comparative Study of

         Paliperidone Palmitate (50 mg eq.) and Risperdal CONSTA (25 mg) in Subjects with Schizophrenia”

102. Principal Investigator

         Protocol: D1140C00006

         “A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZD7325 in the Treatment of Generalized Anxiety Disorder (GAD)”

103. Principal Investigator

         Protocol: RG2417-03

         “A Phase II Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety, Tolerability and Efficacy of RG2417 (Uridine) in Bipolar I Depression”

104. Principal Investigator

         Protocol: 3151A1-4415-NA

         “A Multicenter, Double Blind, Randomized, Placebo-Controlled Study to Evaluate 50 mg of Desvenlafaxine (Pristiq) Extended Release in Functionally Impaired Patients with Major Depressive Disorder”

105. Principal Investigator

         Protocol: H9P-MC-LNBI

         “A Randomized, Double Blind Comparison of LY2216684 and Placebo and Long Term Treatment with LY2216684 in Adult Patients with Major Depressive Disorder”

106. Principal Investigator

         Protocol: 3151A1-4437-US

         “A Randomized, Double-Blind, Parallel Group Study to Compare Discontinuation Symptoms in Abrupt Discontinuation Versus a 1-Week Tapering Regimen in Subjects with Major Depressive Disorder (MDD) Treated for 24 Weeks with Open-Label 50 mg Desvenlafaxine Succinate Sustained-Release Formulation (DVS-SR)”

107. Principal Investigator

         Protocol: 3151A1-3364-US

         “A Multicenter, Parallel-Group, Randomized, 10-Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of Desvenlafaxine Succinate Sustained-Release Formulation (DVS-SR) in the Treatment of Peri- and Post-Menopausal Women with Major Depressive Disorder”

108. Principal Investigator

         Protocol: C10953/3072

         “A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety Armodafinil Treatment (150 mg and 200 mg/day) as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder”

109. Principal Investigator

         Protocol: C10953/3074

         “A 6-Month, Open-Label, Flexible-Dosage (150 mg and 200 mg/day) Extension Study of the Safety and Efficacy of Armodafinil as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder”

110. Principal Investigator

         Protocol: CAGO178C2301

         “An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of the Efficacy and Safety of Agomelatine 0.5 mg and 1.0 mg Sublingual Tablets in Patients with Major Depressive Disorder (MDD)”

111. Principal Investigator

         Protocol: AZD7268

         “A Phase IIa, Multicenter, Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of AZD7268 in Patients with Major Depressive Disorder”

112. Principal Investigator

         Protocol: EFC10438

         “An 8-Week, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Saredutant (100 mg and 30 mg) Once Daily in Combination with Paroxetine 20 mg Once Daily Compared to Saredutant Placebo with Paroxetine 20 mg Once Daily in Patients with Major Depressive Disorder”

113.    Principal Investigator

Protocol:  A5361020

“A Phase 3< Randomized, double-Blind, Parallel Group, 10 Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder”

Sponsor:   Pfizer Inc.                Outpatient Study

114.    Principal Investigator

Protocol:  A5361022

“A 52-eek Open-Label Safety study of PD 0332334 In Subjects with Generalized Anxiety Disorder”

Sponsor:  Pfizer Inc.

115.    Sub-Investigator

Protocol:   CILO522DUS01 Fanapt (iloperidone)

“A 12-week, Randomized Multicenter, Open-Label, Iloperidone, (12-24 mg/day), Flexible dose, Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine, o Aripiprazole (I-FANS)”

Sponsor:  Novartis

116.    Principal Investigator

Protocol:  D4130C00004

“A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an inadequate response to Antidepressant Therapy”

117.    Principal Investigator

Protocol:  D4130C0007

“A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III, Long-Term Safety and Tolerability Study of TC-5214 (S mecamylamine) as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy”

Sponsor:  Astra Zeneca

118.    Sub-Investigator

Procotol:   331-10-227

“A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled trial of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder, the Polaris Trial”

Sponsor:  Otsuka

119.    Sub-Investigator

Protocol:   331-10-238

“A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults with Major Depressive Disorder, the Orion trial”

Sponsor: Otsuka

120.    Principal Investigator

Protocol:  331-10-237

“A Long-term,  Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Maintenance Treatment in Adults with Schizophrenia

Sponsor:  Otsuka

121.    Sub-Investigator

Protocol:  CN 162007

“A Multicenter, Randomized, Double-blind, Active-Controlled, Comparative, Fixed-Dose, Dose Response study of the Efficacy and Safety of BMS-820836 in Patients with Treatmetn Resistant Major Depression”

Sponsor:  Bristol Myers Squibb

122.    Sub-Investigator

Protocol:  CN 162010

“A Multicenter, Double-blind, 58 Week Rollover Study to Assess Safety and Tolerability of BMS-820836 in Patients with Treatment Resistant Major Depression”

Sponsor:  Bristol Myers Squibb

123.    Principal Investigator:

Protocol:  1050304

“A Randomized, 6-Week, Double blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder with Mixed Features”

Sponsor:  Sunovion

124.    Principal Investigator

Protocol:  1050306

“A 12-Week, Open-Label Extension Study for the Treatment of Major Depressive Disorder with Mixed Features.

Sponsor:  Sunovion

125.    Principal Investigator

Protocol:  Lu AA21004_318

A Randomized, Double-blind, Parallel-Group, Active-Controlled, Flexible-Dose Study Evaluating the Effect of Lu AA21004 vs Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing Selective Serotonin Reuptake Inhibitor-Induced Sexual Dysfunction

Sponsor:  Takeda